1stOncology™: Cancer Intelligence Service – Page 14328 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Precigen to Debut Portfolio at Investor Event during the 37th Annual J.P. Morgan Healthcare Conference

On December 31, 2018 Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation (NASDAQ: XON) and a biopharmaceutical company specializing in the development of innovative gene and cellular therapies to improve the lives of patients, reported that the company will hold an investor event on Monday, January 7, 2019 during the 37th Annual J.P. Morgan Healthcare Conference in San Francisco (Press release, Intrexon, DEC 31, 2018, View Source [SID1234532312]). Helen Sabzevari, PhD, President, Precigen, will be presenting at the event.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

The event will include a presentation providing an overview of the company, the long-term vision for the company, and an introduction and overview of current preclinical and clinical programs in immuno-oncology, autoimmune disorders and infectious diseases.

Investors, analysts, media and other interested parties may participate in the event at 3:00 pm PT via live audio webcast, which can be accessed through Intrexon’s website in the Investors section under ‘Events’ at View Source The presentation will be archived on the Intrexon website following the presentation. Spaces are available for individuals who would like to participate in-person at the onsite event. For in-person participation, RSVP is required, and all RSVPs must be received at [email protected] by January 6, 2019 at 5:00 pm PT.

Onconova to Meet Investors and Potential Partners at China Focus and the 37th Annual J.P. Morgan Healthcare Conferences in San Francisco

On December 31, 2018 Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS), reported that Management will meet Investors and potential partners at the 2019 China Focus event, and during the 37th Annual J.P. Morgan Healthcare Conference in San Francisco (Press release, Onconova, DEC 31, 2018, View Source [SID1234532311]).

China Focus@JPM Week Sunday, January 6th
JW Marriott 515 Mason St, 2nd Floor 8:00a-7:00p

J.P. Morgan Conference Monday, January 7th – Thursday, January 10th

Meetings can be scheduled by contacting Suzanne Hutchison ([email protected]).

Heron Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference

On December 31, 2018 Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, reported that Barry D. Quart, Pharm.D., Chief Executive Officer of Heron Therapeutics, will present at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2019, at 5:00 p.m. PST at the Westin St. Francis hotel in San Francisco, CA (Press release, Heron Therapeutics, DEC 31, 2018, View Source [SID1234532310]).

A live webcast of this presentation will be available on the Company’s website at www.herontx.com in the Investor Resources section. A replay of the presentation will be archived on the site for 60 days.

Helix BioPharma Corp. Closes Final Tranche of Private Placement

On December 28, 2019 Helix BioPharma Corp. (TSX, FSE: "HBP") ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, reported it has closed a final tranche of a private placement financing for gross proceeds of CAD348,000 (Press release, Helix BioPharma, DEC 28, 2018, View Source [SID1234533055]).

The terms of the placement are for the purchase of units at $1.20 per unit. Each unit is comprised of one common share and one common share purchase warrant. Each common share purchase warrant will entitle the holder to purchase one common share at an exercise price of $1.50 and have an expiry of five years from the date of issuance. Helix intends to use the net proceeds of the private placement for working capital and research and development activities.

ACM Alpha Consulting Management AG provided financial advisory services to Helix in connection with the private placement.

CTI BioPharma Announces Completion of Enrollment in the Phase 2 PAC203 Study of Pacritinib

On December 28, 2018 CTI BioPharma Corp. (NASDAQ: CTIC) reported the completion of full enrollment of 150 patients in the PAC203 Phase 2 study of pacritinib (Press release, CTI BioPharma, DEC 28, 2018, View Source [SID1234532309]). The Company expects to report the determination of the optimal dose of pacritinib in mid-2019 following a meeting with the U.S. Food and Drug Administration (FDA). Topline efficacy and safety data are expected in the third quarter of 2019, with the new Phase 3 study targeted to commence enrollment in the third quarter of 2019.

As previously announced, the Company has received input from the FDA on key elements of the design of a new randomized Phase 3 study of pacritinib in adult patients with myelofibrosis (primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis) and who have severe thrombocytopenia (as defined by patients with platelet counts of less than 50,000 per microliter), an indication that has been recognized by the medical community as an important unmet medical need. A planned interim safety review by an Independent Data Monitoring Committee (IDMC) is scheduled to occur in the first quarter of 2019.

The PAC203 study is evaluating the safety and efficacy of three dosing schedules (100 mg once daily, 100 mg twice daily and 200 mg twice daily) over 24 weeks in patients with myelofibrosis previously treated with ruxolitinib. More information on the PAC203 trial can be found at ClinicalTrials.gov at View Source